IRIS Accounts Production v25.2.0.378 11275607 Board of Directors 1.1.24 31.12.24 31.12.24 Medium entities true false true true false false true false These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. Ordinary A 0.01000 Ordinary B 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh112756072023-12-31112756072024-12-31112756072024-01-012024-12-31112756072022-12-31112756072023-01-012023-12-31112756072023-12-3111275607ns15:EnglandWales2024-01-012024-12-3111275607ns14:PoundSterling2024-01-012024-12-3111275607ns10:Director12024-01-012024-12-3111275607ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3111275607ns10:MediumEntities2024-01-012024-12-3111275607ns10:Audited2024-01-012024-12-3111275607ns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-01-012024-12-3111275607ns10:Medium-sizedCompaniesRegimeForAccounts2024-01-012024-12-3111275607ns10:FullAccounts2024-01-012024-12-3111275607ns10:OrdinaryShareClass12024-01-012024-12-3111275607ns10:OrdinaryShareClass22024-01-012024-12-3111275607ns10:Director42024-01-012024-12-3111275607ns10:CompanySecretary12024-01-012024-12-3111275607ns10:RegisteredOffice2024-01-012024-12-3111275607ns10:Director32024-01-012024-12-3111275607ns10:Director22024-01-012024-12-3111275607ns5:CurrentFinancialInstruments2024-12-3111275607ns5:CurrentFinancialInstruments2023-12-3111275607ns5:Non-currentFinancialInstruments2024-12-3111275607ns5:Non-currentFinancialInstruments2023-12-3111275607ns5:ShareCapital2024-12-3111275607ns5:ShareCapital2023-12-3111275607ns5:SharePremium2024-12-3111275607ns5:SharePremium2023-12-3111275607ns5:RetainedEarningsAccumulatedLosses2024-12-3111275607ns5:RetainedEarningsAccumulatedLosses2023-12-3111275607ns5:ShareCapital2022-12-3111275607ns5:RetainedEarningsAccumulatedLosses2022-12-3111275607ns5:SharePremium2022-12-3111275607ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-3111275607ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-311127560712024-01-012024-12-3111275607ns5:ReportableOperatingSegment12024-01-012024-12-3111275607ns5:ReportableOperatingSegment12023-01-012023-12-3111275607ns5:TotalReportableOperatingSegmentsIncludingAnyUnallocatedAmount2024-01-012024-12-3111275607ns5:TotalReportableOperatingSegmentsIncludingAnyUnallocatedAmount2023-01-012023-12-3111275607ns15:UnitedKingdom2024-01-012024-12-3111275607ns15:UnitedKingdom2023-01-012023-12-3111275607ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2024-01-012024-12-3111275607ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2023-01-012023-12-3111275607ns5:OwnedAssets2024-01-012024-12-3111275607ns5:OwnedAssets2023-01-012023-12-3111275607112024-01-012024-12-3111275607112023-01-012023-12-3111275607122024-01-012024-12-3111275607122023-01-012023-12-3111275607142024-01-012024-12-3111275607142023-01-012023-12-3111275607152024-01-012024-12-3111275607152023-01-012023-12-311127560712024-01-012024-12-311127560712023-01-012023-12-3111275607ns10:OrdinaryShareClass12023-01-012023-12-3111275607ns10:OrdinaryShareClass22023-01-012023-12-3111275607ns5:FurnitureFittings2023-12-3111275607ns5:FurnitureFittings2024-01-012024-12-3111275607ns5:FurnitureFittings2024-12-3111275607ns5:FurnitureFittings2023-12-3111275607ns5:AdditionsToInvestments2024-12-3111275607ns5:CostValuation2024-12-3111275607ns5:Subsidiary12024-01-012024-12-31112756071ns5:Subsidiary12024-01-012024-12-3111275607ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3111275607ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3111275607ns5:CurrentFinancialInstruments2024-01-012024-12-3111275607ns5:WithinOneYear2024-12-3111275607ns5:WithinOneYear2023-12-3111275607ns5:BetweenOneFiveYears2024-12-3111275607ns5:BetweenOneFiveYears2023-12-3111275607ns5:AllPeriods2024-12-3111275607ns5:AllPeriods2023-12-3111275607ns10:OrdinaryShareClass12024-12-3111275607ns10:OrdinaryShareClass22024-12-31
REGISTERED NUMBER: 11275607 (England and Wales)















DATAPHARM LIMITED

REPORT OF THE DIRECTORS AND

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024






DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

CONTENTS OF THE FINANCIAL STATEMENTS
for the year ended 31 December 2024










Page

Company Information 1

Report of the Directors 2

Independent Auditors' Report 4

Statement of Comprehensive Income 8

Balance Sheet 9

Statement of Changes in Equity 10

Notes to the Financial Statements 11


DATAPHARM LIMITED

COMPANY INFORMATION
for the year ended 31 December 2024







Directors: J P G Wigg
J O A Dibb





Secretary: K Webster





Registered office: Cassini Court
Randalls Way
Leatherhead
Surrey
KT22 7TW





Registered number: 11275607 (England and Wales)





Auditors: Blick Rothenberg Audit LLP
Chartered Accountants
Statutory Auditor
16 Great Queen Street
Covent Garden
London
WC2B 5AH

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

REPORT OF THE DIRECTORS
for the year ended 31 December 2024


The directors present their report with the financial statements of the company for the year ended 31 December 2024.

Principal activity
The principal activity of the company in the year under review was that of the collation and distribution of information and also the provision of regulatory and compliance software solutions to the healthcare and pharmaceutical industry.

Dividends
Dividends of £1,575,000 (2023: £2,095,105) were paid during the year.

Directors
J P G Wigg has held office during the whole of the period from 1 January 2024 to the date of this report.

Other changes in directors holding office are as follows:

P D Facchino - resigned 1 July 2024

J O A Dibb was appointed as a director after 31 December 2024 but prior to the date of this report.

R Cooper ceased to be a director after 31 December 2024 but prior to the date of this report.

Statement of directors' responsibilities
The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

REPORT OF THE DIRECTORS
for the year ended 31 December 2024


Statement as to disclosure of information to auditors
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

On behalf of the board:





J O A Dibb - Director


29 September 2025

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
DATAPHARM LIMITED


Opinion
We have audited the financial statements of Datapharm Limited (the 'company') for the year ended 31 December 2024 which comprise the Statement of Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Directors has been prepared in accordance with applicable legal requirements.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
DATAPHARM LIMITED


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page two, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
DATAPHARM LIMITED


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with the directors and other management, and from our commercial knowledge and experience of the company's sector;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, taxation legislation and data protection;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:
- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:
- performed analytical procedures to identify any unusual or unexpected relationships;
- tested a sample of journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:
- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance; and
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' Report.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
DATAPHARM LIMITED


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Nicholas Winters (Senior Statutory Auditor)
for and on behalf of Blick Rothenberg Audit LLP
Chartered Accountants
Statutory Auditor
16 Great Queen Street
Covent Garden
London
WC2B 5AH

29 September 2025

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

STATEMENT OF COMPREHENSIVE INCOME
for the year ended 31 December 2024

2024 2023
Notes £    £   

TURNOVER 4 10,162,477 7,617,712

Cost of sales (528,279 ) (509,939 )
GROSS PROFIT 9,634,198 7,107,773

Administrative expenses (9,571,964 ) (6,350,341 )
62,234 757,432

Other operating income 541,095 307,245
OPERATING PROFIT 6 603,329 1,064,677

Interest receivable and similar income 93,648 101,295
696,977 1,165,972

Interest payable and similar expenses 7 (4,267 ) -
PROFIT BEFORE TAXATION 692,710 1,165,972

Tax on profit 8 (246,296 ) (121,617 )
PROFIT FOR THE FINANCIAL YEAR 446,414 1,044,355

OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME FOR THE
YEAR

446,414

1,044,355

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

BALANCE SHEET
31 December 2024

2024 2023
Notes £    £   
FIXED ASSETS
Tangible assets 10 216,579 251,693
Investments 11 2,082,748 -
2,299,327 251,693

CURRENT ASSETS
Debtors 12 5,932,178 7,752,566
Cash at bank 6,516,911 5,329,951
12,449,089 13,082,517
CREDITORS
Amounts falling due within one year 13 (2,527,478 ) (2,329,173 )
NET CURRENT ASSETS 9,921,611 10,753,344
TOTAL ASSETS LESS CURRENT LIABILITIES 12,220,938 11,005,037

CREDITORS
Amounts falling due after more than one
year

14

(970,000

)

-

PROVISIONS FOR LIABILITIES 16 (75,000 ) -

DEFERRED INCOME 17 (9,958,465 ) (8,658,978 )
NET ASSETS 1,217,473 2,346,059

CAPITAL AND RESERVES
Called up share capital 18 902 902
Share premium 127,431 127,431
Retained earnings 1,089,140 2,217,726
SHAREHOLDERS' FUNDS 1,217,473 2,346,059

The financial statements were approved by the Board of Directors and authorised for issue on 29 September 2025 and were signed on its behalf by:





J O A Dibb - Director


DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

STATEMENT OF CHANGES IN EQUITY
for the year ended 31 December 2024

Called up
share Retained Share Total
capital earnings premium equity
£    £    £    £   
Balance at 1 January 2023 902 3,268,476 127,431 3,396,809

Changes in equity
Dividends - (2,095,105 ) - (2,095,105 )
Total comprehensive income - 1,044,355 - 1,044,355
Balance at 31 December 2023 902 2,217,726 127,431 2,346,059

Changes in equity
Dividends - (1,575,000 ) - (1,575,000 )
Total comprehensive income - 446,414 - 446,414
Balance at 31 December 2024 902 1,089,140 127,431 1,217,473

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 December 2024


1. STATUTORY INFORMATION

Datapharm Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in Sterling (£), which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements are prepared under the historical cost convention and modified to include certain items at fair value as explained further below.

Financial Reporting Standard 102 - reduced disclosure exemptions
The company has taken advantage of the following disclosure exemption in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

the requirements of Section 7 Statement of Cash Flows.

Going concern
The directors have considered post year end trading, financial results and cash reserves and after making enquiries, the directors have a reasonable expectation that the group has adequate resources to continue in operational existence and will continue to meet its liabilities as they fall due for the foreseeable future, being a period of at least twelve months from the date these financial statements are approved. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover
Turnover is measured at the fair value of the consideration receivable for the sale of services in the ordinary course of the business, excluding discounts and value added tax. Where the company enters a contract for the provision of services which extend over a period of time, turnover is recognised in the period in which services are provided in accordance with the stage of completion of the transaction.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Office equipment - 50% on cost
Fixtures & fittings - 20% on cost

Tangible fixed assets are stated at their historic cost price less accumulated depreciation. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for use. The assets residual values, useful lives and depreciation methods are reviewed if there is an indication of significant change since the last reporting date.

On disposal the difference between net proceeds and carrying amount of the item sold is recognised in administrative expenses.

Investments in subsidiaries
Investments in subsidiaries are measured at cost less accumulated impairment, where applicable.

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2024


2. ACCOUNTING POLICIES - continued

Financial instruments
Financial instruments are classified by the directors as basic or other following the conditions in FRS 102 Section 11. Basic financial instruments are recognised at amortised cost. The company has no other financial instruments.

Trade debtors are recognised and carried forward at invoiced amounts less provision for doubtful debts. All other debtors are recognised at transaction price less impairment if applicable.

Cash at bank and in hand comprises of cash that is readily available for use within the business and is held at financial institutions or as cash in hand.

Creditors falling due within one year and due in more than one year are measured and carried forward at the transaction price.

Taxation
Taxation for the year comprises current and deferred tax. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.

Where applicable, the company claims the research and development expenditure credit available and this is shown within other operating income with the relevant tax charge reported within taxation.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Operating leases
Rentals paid under operating leases are charged to the profit or loss on a straight line basis over the term of the lease.

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2024


3. SIGNIFICANT JUDGEMENTS AND ESTIMATES

The preparation of the financial statements requires management to make judgements, estimates and assumptions in the application of accounting policies that affect reported amounts of assets, liabilities and profit and loss. In preparing these financial statements, management have made the following key judgements and estimates which are significant to the financial statements.

Recoverability of trade debtors
Trade debtors are recognised to the extent that they are judged recoverable. Provisions are made specifically against invoices where recoverability is uncertain.

Management make allowances for doubtful debts each year based on an assessment of the recoverability of debtors. Allowances are applied to debtors where events or changes in circumstances indicate that the carrying amounts may not be recoverable. Client creditworthiness, current economic trends, ageing of the debt and management experience are all considered when providing for doubtful debts.

The amount of the provision recognised in the profit or loss is the excess of the asset's carrying amount over the present value of estimated future cash flows.

Recoverability of intercompany balances
Management have made key judgements regarding the recoverability of related party debts. The recoverability of debts is assessed by reference to the related company performance and profit forecasts, and adjustments to the provisions are made as required.

Leasing
Management determine whether leases entered into are an operating or finance lease. These decisions depend on an assessment of whether the risks and rewards of ownership have been transferred from the lessor to the company and are assessed on a lease by lease basis. The transfer of risk is assessed by reference to the evaluation of the terms and conditions of the arrangement, the estimated useful life of the asset and whether an option to purchase exists at the end of the lease term.

4. TURNOVER

The turnover and profit before taxation are attributable to the one principal activity of the company.

An analysis of turnover by class of business is given below:

2024 2023
£    £   
Provision of data services 10,162,477 7,617,712
10,162,477 7,617,712

An analysis of turnover by geographical market is given below:

2024 2023
£    £   
United Kingdom 8,800,495 6,627,409
Rest of World 1,361,982 990,303
10,162,477 7,617,712

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2024


5. EMPLOYEES AND DIRECTORS
2024 2023
£    £   
Wages and salaries 3,296,516 2,327,760
Social security costs 386,942 280,019
Other pension costs 284,381 133,950
3,967,839 2,741,729

The average number of employees during the year was as follows:
2024 2023

Administration 8 8
Client support 16 13
Product group 21 17
Directors 2 3
47 41

2024 2023
£    £   
Directors' remuneration 131,424 79,503
Directors' pension contributions to money purchase schemes 9,706 6,507

6. OPERATING PROFIT

The operating profit is stated after charging:

2024 2023
£    £   
Depreciation - owned assets 67,439 20,978
One time cost for purchase of subsidiary 173,430 -
Auditors remuneration 34,500 15,000
Operating lease rentals 181,232 96,047
Defined pension contributions 284,381 133,950

7. INTEREST PAYABLE AND SIMILAR EXPENSES
2024 2023
£    £   
Other interest payable 4,267 -

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2024


8. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2024 2023
£    £   
Current tax:
UK corporation tax 246,296 121,617
Tax on profit 246,296 121,617

UK corporation tax has been charged at 25% (2023 - 23.52%).

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

2024 2023
£    £   
Profit before tax 692,710 1,165,972
Profit multiplied by the standard rate of corporation tax in the UK of 25%
(2023 - 23.521%)

173,178

274,248

Effects of:
Expenses not deductible for tax purposes 45,244 6,968
Adjustments to tax charge in respect of previous periods (39 ) -
Deferred tax not recognised 27,913 (159,599 )
Total tax charge 246,296 121,617

As at 31 December 2024, the company has corporation tax losses of £16,231,845 (2023: £16,188,281) and timing differences of £216,802 (2023: £130,191) carried forward, resulting in a deferred tax asset of £4,112,162 (2023: £4,079,618). This deferred tax asset has not been recognised on the basis that the group is forecasted to generate sufficient tax losses to relieve any future taxable profits and therefore the tax losses brought forward are not expected to be utilised.

9. DIVIDENDS
2024 2023
£    £   
Ordinary A shares of £0.01 each
Interim 1,353,993 1,801,116
Ordinary B shares of £0.01 each
Interim 221,007 293,989
1,575,000 2,095,105

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2024


10. TANGIBLE FIXED ASSETS
Office
equipment
£   
Cost
At 1 January 2024 720,728
Additions 32,325
Disposals (473,442 )
At 31 December 2024 279,611
Depreciation
At 1 January 2024 469,035
Charge for year 67,439
Eliminated on disposal (473,442 )
At 31 December 2024 63,032
Net book value
At 31 December 2024 216,579
At 31 December 2023 251,693

11. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
Cost
Additions 2,082,748
At 31 December 2024 2,082,748
Net book value
At 31 December 2024 2,082,748

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Original Digital Limited
Registered office: Cassini Court, Randalls Way, Leatherhead, Surrey, KT22 7TW
Nature of business: Information technology consultancy
%
Class of shares: holding
Ordinary 100.00

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2024


12. DEBTORS
2024 2023
£    £   
Amounts falling due within one year:
Trade debtors 3,869,365 4,192,108
Amounts owed by group undertakings 1,114,360 1,764,838
Other debtors 591,226 334,731
Prepayments and accrued income 357,227 418,807
5,932,178 6,710,484

Amounts falling due after more than one year:
Amounts owed by group undertakings - 1,042,082

Aggregate amounts 5,932,178 7,752,566

The amounts owed by group undertakings falling due after more than one year as at 31 December 2023 were subject to 12% interest per annum and were repaid early in September 2024.

All other amounts owed by group undertakings are interest free and repayable on demand.

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 304,838 110,515
Amounts owed to group undertakings 472,693 49,351
Taxation and social security 525,191 978,291
Other creditors 17,119 1,013
Accruals and deferred income 1,207,637 1,190,003
2,527,478 2,329,173

The amounts owed to group undertakings are repayable on demand. Those amounts shown as at 31 December 2024 are interest free whereas the amounts shown as at 31 December 2023 were subject to an arm's length market rate of interest.

14. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2024 2023
£    £   
Deferred consideration payable 970,000 -

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2024


15. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2024 2023
£    £   
Within one year 205,168 119,681
Between one and five years 564,212 769,380
769,380 889,061

16. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Dilapidations provision 75,000 -

17. DEFERRED INCOME
2024 2023
£    £   
Deferred income 9,958,465 8,658,978

18. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
77,500 Ordinary A £0.01 775 775
12,650 Ordinary B £0.01 127 127
902 902

The Ordinary A shares and Ordinary B shares rank pari passu in relation to dividend payments and any other distributions. Only the Ordinary A shares carry voting rights.

19. ULTIMATE PARENT COMPANY

The immediate parent company is Summer Bidco Limited. The ultimate parent company is Summer Topco Limited.

The accounts of Datapharm Limited are included in the consolidated group accounts of Summer Topco Limited. Summer Topco Limited is registered in England and Wales and its financial statements can be obtained from its registered office at Cassini Court, Randalls Way, Leatherhead, Surrey, KT22 7TW.

20. PENSION COMMITMENTS

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. Contributions totalling £Nil (2023: £Nil) were payable to the fund at the balance sheet date.

DATAPHARM LIMITED (REGISTERED NUMBER: 11275607)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2024


21. RELATED PARTY DISCLOSURES

The company has taken advantage of the exemption contained in Financial Reporting Standard 102 section 33 "Related Party Disclosures" from disclosing transactions with entities which are a wholly owned part of the group.

22. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is CGE Partners LLP, a limited liability partnership registered in England and
Wales.